Monday, BioCryst Pharmaceuticals, Inc. (BCRX) announced the approval of its once-daily oral prophylactic treatment, Orladeyo also known as berotralstat, for preventing hereditary angioedema attacks in adults and pediatric patients aged 12 and above by the Federal Commission for Protection against Health Risks or COFEPRIS in Mexico.
The company stated that it holds an exclusive partnership with Pint Pharma GmbH to register and market Orladeyo in the pan-Latin America area.
According to the agreement, Pint is tasked with securing and managing all marketing authorizations and handling the commercialization of Orladeyo in Latin America.
The company revealed that Orladeyo had previously received approval from regulatory bodies in Chile, Argentina, and Brazil in this region.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.